Lysogene Completes Enrollment in First International Pivotal Observational Study in MPS IIIA

Lysogene Completes Enrollment in First International Pivotal Observational Study in MPS IIIA 150 150 Lysogene

May 30th, 2017

  • Rapid recruitment of 23 patients in less than a year
  • Consensually agreed assessment tools (BSID-III, VABS-II) for cognitive assessment & behavior
FOR IMMEDIATE RELEASE

PARIS, France, and CAMBRIDGE, MA, US – May 30th, 2017, 7:00 am CET – Lysogene (FR0013233475 –

LYS), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced the completion of enrollment in its “Sanfilippo A Multi- national Observational Study” (SAMOS). Sanfilippo A is also known as Mucopolysaccharidosis Type IIIA (MPS IIIA).

SAMOS is particularly important as there is currently no validated biomarker in MPS IIIA that reflects CNS disease progression and response to future therapy. SAMOS has therefore been designed to evaluate clinical change in untreated MPS IIIA patients. As agreed with the regulatory authorities, this international multi-center study is to function as a non-concurrent control group for the upcoming Lysogene Phase II/III pivotal gene therapy trial, scheduled to start during the first quarter of 2018.

Lysogene has taken a very proactive and rigorous approach to gaining a better understanding of MPS IIIA,” said Dr. Benedicte Heron, neuro-pediatrician (Armand-Trousseau Hospital, APHP Paris, France). “The

company’s efforts in running this observational study will support its own plans for future research and therapy development while also aiding the scientific community as a whole.

Enrollment of the 23 children from 5 countries has been rapid, reflecting the strong interest from the key opinion leaders running our clinical sites and the network of patient associations to address the significant unmet needs in MPS IIIA,” stated Samantha Parker, Chief Patient Access Officer at Lysogene.

In designing SAMOS, Lysogene established the first international neurologist and neuropsychologist MPS IIIA expert group. This group determined that the most scientifically rigorous and relevant primary endpoint was cognitive assessment using the Bayley Scales of Infant and Toddler Development, 3rd edition (BSID-III). The Vineland Adaptive Behavior Scale, 2nd edition (VABS-II) was determined to be the most appropriate as a secondary endpoint measure.

Further validating the choice of endpoints for neuronopathic MPS, a consensus meeting, among international experts, was organised in London, 2-3 December 2016, by an academic group in consultation with the UK Society for Mucopolysaccharide Diseases and US National MPS Society, and chaired by Elsa Shapiro1. From all the available instruments the BSID-III is recommended to measure cognitive outcomes and the recommended instrument to measure adaptive behavior is the VABS-II, using the extended interview format (van der Lee, 2017).2

Lysogene previously issued baseline data from SAMOS assessing cognitive age using the BSID-III in the first 15 patients, aged between 3 and 8 years old, which confirmed the progressive intellectual decline, hyperactivity and behavior changes in these individuals.

Lysogene has also successfully completed a Phase I/II trial and 5-year follow-up study of four MPS IIIA patients with no adverse events related to the treatment.3

Lysogene is Targeting Treatment for the Neurological Symptoms of MPS IIIA:

MPS IIIA is a lethal CNS disease requiring targeted treatment. Lysogene’s gene therapy candidate for MPS IIIA is a rAAV vector serotype rh.10 carrying the gene coding for SGSH. This in vivo gene therapy offers the possibility of a one-time treatment by inserting a healthy copy of the SGSH gene and allowing the body to start making the missing enzyme, therefore slowing or halting disease progression. Lysogene’s gene therapy is delivered directly to the CNS in one neurosurgical procedure. By delivering the missing SGSH gene, Lysogene believes MPS IIIA patients will be provided a permanent source of functional enzyme in the brain that reverses phenotypic abnormalities of CNS neural cells.

For more information on SAMOS: www.ClinicalTrials.gov Identifier: NCT02746341.

About Lysogene

Lysogene is a clinical stage biotechnology company pioneering the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need. Since 2009, Lysogene has established a solid platform and network, with lead products in MPS IIIA and GM1 Gangliosidosis, to become a global leader in orphan CNS diseases. Lysogene has also obtained orphan drug designation by the EMA and FDA and rare pediatric designation by the FDA for its MPS IIIA program. Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475)

For more information: www.lysogene.com.

1 Shapiro Neuropsychology Consulting, LLC, Portland, OR, USA and Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA 2 J.H. van der Lee, et al., Cognitive endpoints for therapy development for neuronopathicmucopolysaccharidoses: Results of a consensus procedure, Mol. Genet. Metab. (2017), http://dx.doi.org/10.1016/j.ymgme.2017.05.004

3 Tardieu, M., et al. Intracerebral Administration of Adeno-Associated Viral Vector Serotype rh.10 Carrying Human SGSH and SUMF1 cDNAs in Children with Mucopolysaccharidosis Type IIIA Disease: Results of a Phase I/II Trial, Human Gene Therapy (2014), http://online.liebertpub.com/doi/abs/10.1089/hum.2013.238

Contacts
Media: Investors:
Europe
Annie-Florence Loyer Chris Maggos
NewCap LifeSci Advisors
afloyer@newcap.fr chris@lifesciadvisors.com
+ 33 6 88 20 35 59 +41 79 367 6254
+ 33 1 44 71 00 12
North America
Marion Janic
RooneyPartners
mjanic@rooneyco.com
+ 1 (212) 223-4017

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.

    Back to top